Int. J. Curr. Res. Med. Sci. (2023). 9(11): 16-22

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 9, Issue 11 -2023

DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.003

COVID-19 and Blood Coagulation: Implications for Hemostasis

[*]Emmanuel Ifeanyi Obeagu[1], Getrude Uzoma Obeagu[2] and Matthew Chibunna Igwe[3]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science,Kampala International University, Uganda.

[3]Department of Public Health, Kampala International University, Uganda.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a global health crisis with multifaceted clinical manifestations. Apart from respiratory distress, increasing evidence highlights the intricate relationship between COVID-19 and blood coagulation, significantly impacting hemostasis mechanisms. This paper aims to elucidate the complex interplay between COVID-19 and blood coagulation, delineating the implications for hemostasis, thrombotic events, and their clinical repercussions.COVID-19 is recognized for its diverse clinical presentations, extending beyond respiratory involvement. A growing body of research underscores the association between COVID-19 and coagulopathy, revealing disturbances in various facets of blood coagulation. This review synthesizes current knowledge, exploring the underlying mechanisms of COVID-19-induced coagulopathy and its profound implications for hemostasis.Moreover, this paper delves into the impact of COVID-19 on fundamental hemostasis mechanisms, encompassing disruptions in clotting factors, platelet function, fibrinolysis, and endothelial integrity. A comprehensive understanding of these interactions is pivotal in shaping clinical management strategies and improving outcomes for individuals affected by COVID-19.

Keywords: COVID-19, SARS-CoV-2, Blood Coagulation, Hemostasis, Thrombosis, Coagulopathy

Introduction

The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has sparked a global health crisis of unprecedented proportions. While respiratory complications have been the hallmark of this viral illness, mounting evidence has underscored the intricate connection between COVID-19 and aberrant blood coagulation, presenting profound implications for hemostasis and thrombotic events [1-7].COVID-19 manifests with a spectrum of clinical manifestations, extending beyond respiratory distress to encompass systemic complications affecting various organ systems. Of notable concern is the increasing recognition of coagulation abnormalities and thrombotic events observed in a subset of COVID-19 patients. This review seeks to unravel the intricate relationship between COVID-19 and blood coagulation, elucidating the underlying mechanisms and highlighting the consequential implications for hemostasis [8-11].

The convergence of COVID-19 with coagulation abnormalities has raised pertinent questions regarding the pathophysiological mechanisms driving these phenomena. Emerging evidence suggests multifaceted interactions, involving endothelial dysfunction, dysregulated inflammatory responses, heightened platelet activation, and disruptions in the coagulation cascade, contributing to a prothrombotic state in severe COVID-19 cases.Moreover, this paper aims to explore the impact of COVID-19 on fundamental hemostatic mechanisms, encompassing alterations in clotting factors, platelet function, fibrinolysis, and endothelial integrity. These perturbations in hemostasis not only contribute to the thrombotic complications observed in COVID-19 patients but also potentially influence disease severity and clinical outcomes.Understanding the implications of COVID-19 on hemostasis holds pivotal significance in clinical practice. The identification of thrombotic risk factors, prognostication of disease severity based on coagulation profiles, and delineating optimal anticoagulation strategies are pressing concerns in managing COVID-19-associated coagulopathy.This paper aims to comprehensively dissect the intricate relationship between COVID-19 and blood coagulation, shedding light on the underlying mechanisms driving coagulopathy and the consequential implications for hemostasis. By synthesizing current knowledge, it endeavors to provide insights into the pathophysiological intricacies and guide strategies for optimized clinical management in this evolving landscape of COVID-19-associated coagulation abnormalities.

COVID-19 and Coagulopathy

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with a spectrum of clinical manifestations, including coagulopathy that significantly impacts disease severity and patient outcomes. COVID-19-associated coagulopathy has garnered substantial attention due to its complex and multifaceted nature, leading to thrombotic complications and contributing to morbidity and mortality in affected individuals [12-16].COVID-19 is known to induce endothelial injury, leading to endotheliitis and disruption of the endothelial barrier. This endothelial dysfunction contributes to a prothrombotic state, promoting microvascular thrombosis and contributing to systemic organ damage [17-19].Severe COVID-19 cases are characterized by a dysregulated immune response and cytokine storm, resulting in systemic inflammation. The cytokine release, particularly interleukin-6 (IL-6), activates coagulation pathways, leading to a hypercoagulable state and an increased risk of thrombosis [20-22].SARS-CoV-2 infection can trigger platelet activation, causing an increase in platelet-monocyte aggregates and platelet hyperreactivity. This heightened platelet activation contributes to the formation of microthrombi and disseminated intravascular coagulation (DIC) in severe cases [23].COVID-19-induced coagulopathy involves perturbations in the coagulation cascade, including elevated levels of D-dimers, fibrinogen, and von Willebrand factor. Concurrently, there might be a decrease in anticoagulant factors, contributing to a prothrombotic state [24-25].Patients with severe COVID-19 exhibit an

increased incidence of venous thromboembolism (VTE), pulmonary embolism (PE), stroke, and myocardial infarction. These thrombotic events are associated with adverse outcomes, necessitating vigilant monitoring and prompt intervention.Moreover, ongoing research endeavors are focused on elucidating predictive biomarkers, refining treatment protocols, and investigating the long-term consequences of COVID-19-induced coagulopathy to optimize management strategies and enhance patient care.The complex interplay between COVID-19 and coagulopathy underscores the need for comprehensive approaches to address the hemostatic alterations associated with this viral illness. Continued research efforts aimed at deciphering the underlying mechanisms and identifying effective therapeutic interventions are crucial in mitigating the thrombotic complications and reducing the disease burden imposed by COVID-19-associated coagulopathy.

Hemostasis Implications

The implications of COVID-19 on hemostasis are profound and multifaceted, encompassing alterations in various components of the coagulation system, platelet function, endothelial integrity, and fibrinolytic pathways. The dysregulation of hemostasis mechanisms in COVID-19 contributes significantly to disease severity, thrombotic complications, and adverse clinical outcomes [26].COVID-19 is associated with changes in clotting factors, including elevated levels of fibrinogen, von Willebrand factor, and factor VIII. These alterations contribute to a hypercoagulable state and promote thrombus formation, predisposing patients to venous and arterial thrombotic events.SARS-CoV-2 infection triggers platelet activation and aggregation, leading to increased platelet-monocyte aggregates and platelet hyperreactivity. The enhanced platelet activation contributes to microvascular thrombosis and systemic inflammation, exacerbating the coagulopathy observed in severe cases.COVID-19-induced endotheliitis and endothelial injury compromise endothelial function, resulting in impaired antithrombotic properties and a prothrombotic state. This endothelial dysfunction contributes to microvascular thrombosis and vascular complications seen in severe COVID-19 patients.COVID-19 is associated with impaired fibrinolysis, leading to reduced clot breakdown and fibrin accumulation. Altered fibrinolytic pathways contribute to the formation of fibrin-rich microthrombi, contributing to organ damage and thrombotic events.The hemostatic alterations in COVID-19 patients culminate in an increased risk of thrombotic complications, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, myocardial infarction, and systemic thromboembolic events. These complications significantly impact patient morbidity and mortality.The implications of COVID-19 on hemostasis underscore the critical need for vigilant monitoring of coagulation parameters, risk stratification for thrombotic events, and tailored therapeutic interventions. Anticoagulation strategies, including prophylactic and therapeutic anticoagulation, are being explored to mitigate thrombotic risks in severely ill COVID-19 patients.

Clinical Implications and Management

The clinical implications of COVID-19-induced coagulopathy are far-reaching, necessitating a comprehensive approach to manage thrombotic risks, mitigate complications, and improve patient outcomes. Addressing these implications involves vigilant monitoring, risk stratification, and implementing appropriate management strategies tailored to the individual patient's needs [27].Routine monitoring of coagulation parameters, including D-dimers, fibrinogen, and platelet counts, assists in assessing thrombotic risk and disease severity in COVID-19 patients. Elevated D-dimer levels, in particular, serve as prognostic markers for severe disease and increased thrombotic propensity.Implementing thromboprophylaxis protocols, including pharmacological agents such as low molecular weight heparin (LMWH) or unfractionated heparin (UFH), in hospitalized COVID-19 patients based on individual risk stratification and clinical severity. Prophylactic anticoagulation aims to prevent venous thromboembolism (VTE) in high-risk individuals without increasing bleeding complications.In severely ill COVID-19

patients with confirmed thrombotic complications or markedly elevated D-dimer levels, therapeutic anticoagulation might be warranted. However, the decision to initiate therapeutic anticoagulation should consider the individual's bleeding risk and clinical status.Tailoring treatment strategies based on a patient's clinical condition, comorbidities, and coagulation profile is pivotal. Individualized approaches aim to balance the thrombotic risks and bleeding complications in COVID-19 patients.Regular monitoring of coagulation parameters and clinical status is essential in assessing the response to anticoagulation therapy, identifying complications, and adjusting treatment regimens accordingly. Long-term follow-up to manage thrombotic risks post-discharge is also crucial.Considering thrombotic complications in specific scenarios, such as COVID-19 patients in critical care settings, pregnant women, and pediatric patients, to tailor appropriate management strategies addressing the unique needs of these populations.Ongoing research endeavors focus on refining treatment protocols, investigating optimal anticoagulation strategies, evaluating novel therapies, and identifying predictive biomarkers to enhance risk stratification and guide management decisions.Collaboration among healthcare professionals, including hematologists, pulmonologists, intensivists, and thrombosis experts, facilitates optimal patient management and decision-making in addressing COVID-19-associated coagulopathy.Strategies for managing COVID-19-associated coagulopathy remain an active area of research and clinical exploration. The dynamic nature of this viral illness mandates continual reassessment of treatment protocols and integration of emerging evidence to refine management strategies, ultimately aiming to reduce thrombotic risks and improve outcomes for affected individuals.

Future Directions

Understanding the complexities of COVID-19-associated coagulopathy remains a crucial area of exploration, and future directions in research and clinical practice aim to address key aspects to enhance patient care and outcomes.Continued research efforts focus on identifying reliable predictive biomarkers that can stratify thrombotic risk and predict disease severity in COVID-19 patients. Identification of specific markers indicative of hypercoagulability or susceptibility to thrombotic events could aid in risk assessment and guide therapeutic interventions.Further refinement and optimization of anticoagulation protocols, including dosage, duration, and selection of anticoagulants, are essential. Tailoring anticoagulation regimens based on individual patient characteristics, disease severity, and coagulation profiles to balance thrombotic risks and bleeding complications are areas of ongoing research.Investigation of novel therapeutic interventions targeting specific components of the coagulation cascade or addressing endothelial dysfunction in COVID-19 patients. This includes exploring potential agents that modulate platelet function, mitigate endothelial injury, or modulate the inflammatory response to improve hemostasis and reduce thrombotic risks.Longitudinal studies focusing on the long-term consequences of COVID-19-associated coagulopathy are necessary to understand the persistence of thrombotic risks beyond the acute phase of illness. Strategies for post-discharge thromboprophylaxis and management to reduce long-term thrombotic complications need further investigation.Rigorous clinical trials evaluating various anticoagulation strategies, therapeutic agents, and risk mitigation approaches in COVID-19 patients are pivotal to establish evidence-based guidelines and refine best practices in managing coagulopathy associated with this viral illness.Development and validation of comprehensive risk stratification models integrating clinical, laboratory, and imaging data to predict thrombotic events, guide therapeutic decisions, and improve patient outcomes.Continued collaboration among researchers, clinicians, and experts across disciplines to share insights, data, and experiences, facilitating a comprehensive understanding of COVID-19-associated coagulopathy and enabling the translation of research findings into clinical practice.Continued research endeavors, clinical collaborations, and advancements in understanding the pathophysiology of COVID-19-associated coagulopathy are pivotal in refining management

strategies, optimizing patient care, and mitigating thrombotic risks in affected individuals.

Conclusion

The intricacies of COVID-19-associated coagulopathy have unveiled a critical intersection between viral infection and hemostasis, presenting a multifaceted challenge in clinical management. The evolving understanding of the interplay between COVID-19 and coagulation disturbances underscores the imperative need for continued research, vigilant monitoring, and refined management strategies to improve patient outcomes. Advancing our understanding of the pathophysiological mechanisms, refining therapeutic approaches, and integrating multidisciplinary efforts are pivotal in addressing the hemostatic implications of COVID-19. By embracing these future directions, healthcare providers can optimize management strategies, enhance patient care, and mitigate the impact of coagulopathy in the context of this global health crisis.

References

1. Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, De Wulf A, Grover J, Papadimos TJ, Bloem C, Galwankar SC. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. Journal of global infectious diseases. 2020;12(2):47.
2. Ogar CO, Okoroiwu HU, Obeagu EI, Etura JE, Abunimye DA. Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. Transfusion Clinique et Biologique. 2021;28(1):68-72.
3. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487. links/617acdd03c987366c3f8b3f1/Covid-19-and-Sickle-Cell-Anemia-Susceptibility-and-Severity.pdf.
4. Obeagu EI. COVID 19: Factors Associated with Implementation and Practice of Covid-19 Prevention. Int. J. Adv. Multidiscip. Res. 2022;9(9): 37-42.DOI: 10.22192/ijamr.2022.09.09.004
5. Nnodim J, Njoku-Obi T, Ohalete C, Obeagu EI. Perspective of Covid 19 Hesistancy. Madonna University journal of Medicine and Health Sciences. 2022;2(1):235-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/50.
6. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO. INFANTS IMMUNIZATION: CHALLENGES OF OTHER VACCINES DUE TO COVID-19 PANDEMIC. Journal of Bioinnovation. 2021;10(4):1056-66.links/6105aef21e95fe241a9e607a/INFANTS-IMMUNIZATION-CHALLENGES-OF-OTHER-VACCINES-DUE-TO-COVID-19-PANDEMIC.pdf.
7. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Chukwueze CM. A Systematic Review on the role of untreated inflammation of the genital tract in SARS COV 2 transmission. Madonna University journal of Medicine and Health Sciences. 2023;3(1):19-24.https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/98.
8. Obeagu EI, Hamisi S, Bunu UO. An update on cytokine storm in covid-19 infection: Pivotal to the survival of the patients. Int. J. Adv. Res. Biol. Sci. 2023;10(3): 171-80.DOI: 10.22192/ijarbs.2023.10.03.020
9. Obeagu EI. Mental Health Care during the COVID-19 Pandemic. Journal of Public Health and Nutrition. 2020;3(5).links/6012dc1792851c2d4dfebad6/Mental-Health-Care-during-the-COVID-19-Pandemic.pdf.
10. Asogwa EI, Obeagu EI, Abonyi OS, Elom CO, Udeoji DU, Egbumike CJ, Agunwah EU, Eze CN, Akamike IC, Esimai BN. Mitigating the Psychological Impacts of COVID-19 in Southern Nigeria; Public Awareness of Routine Exercises and Preventive Measures. Journal of

Pharmaceutical Research International. 2021;33(30A):72-83.
11. Obeagu EI, Babar Q, Vincent CC, Okafor CJ, Eze R, Chijioke UO, Ibekwe AM, Uduchi IO. Pulmonary Embolism in Covid-19 Pandemic: A Threat to Recovery of the Infected Patients. Journal of Pharmaceutical Research International. 2021;33(42A):90-8.
12. Kolodziej LM, van Lelyveld SF, Haverkort ME, Mariman R, Sluiter-Post JG, Badoux P, de Koff EM, Koole JC, Miellet WR, Swart AN, Coipan EC. High Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission Rates Detected by Dense Saliva Sampling. Clinical Infectious Diseases. 2022;75(1): e10-9.
13. Obeagu EI, Babar Q, Uduchi IO, Ibekwe AM, Chijioke UO, Okafor CJ, Vincent CC. An Update on Transfusion Related Immunomodulation (TRIM) in a Time of COVID-19 Pandemic. Journal of Pharmaceutical Research International. 2021;33(42A):135-46.
14. Okorie N, Adeniran OC, Adimabua OP, Obeagu EI, Anastasia E. Pathological Changes among Norvegicus Rattus Exposed on Novel Smoked Bambusa Vulgaris (Bamboo) Leaf: Cigarette Substitute during COVID-19 Lockdown in Nigeria. Journal of Advances in Medical and Pharmaceutical Sciences. 2022;24(7):30-9.
15. Nakyeyune S, Ikpenwa JN, Madekwe CC, Madekwe CC, Tolulope AA, Ajayi DT, Obeagu EI, Hassan AO. COVID 19 Omicron: The Origin, Presentation, Diagnosis, Prevention and Control. Asian Journal of Research in Infectious Diseases. 2022:25-33.
16. Etido A, Obeagu EI, Okafor CJ, Chijioke UO, Vincent CC, Mojo-Eyes GC. The Dynamics of Innate and Adaptive Immune Response to Sars Cov-2 Infection and Its Limitations in Human Beings. Journal of Pharmaceutical Research International. 2021;33(45A):10-25.
17. Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacologica Sinica. 2023;44(4):695-709.
18. Obeagu EI, Obeagu GU, Chukwueze CM, Ngwoke AO. Inappropriate use of personal protective equipment among health workers: A review of associated factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 27-34.DOI: 10.22192/ijcrcps.2023.10.08.004
19. Obeagu EI, Nwosu DC, Obeagu GU. Interleukin-6 (IL-6): A Major target for quick recovery of COVID-19 patients. **Int. J. Curr. Res. Biol. Med. (2022). 7(2): 1-19. DOI:** 10.22192/ijcrbm.2022.07.02.001
20. Mohamed Khosroshahi L, Rezaei N. Dysregulation of the immune response in coronavirus disease 2019. Cell Biology International. 2021;45(4):702-7.
21. Ifeanyi OE, Mercy OH, Prayer NN, Chijindu OH. Cytokines, coagulation profile and haematological changes in covid 19 patients as indicators of their health staus: A review. European Journal of Biomedical. 2020;7(7):724-9.links/5f083f4e299bf188161034aa/CYTOKINES-COAGULATION-PROFILE-AND-HAEMATOLOGICAL-CHANGES-IN-COVID-19-PATIENTS-AS-INDICATORS-OF-THEIR-HEALTH-STATUS-A-REVIEW.pdf.
22. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023;11(1):25-30.
23. Li T, Yang Y, Li Y, Wang Z, Ma F, Luo R, Xu X, Zhou G, Wang J, Niu J, Lv G. Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein. The Journal of Clinical Investigation. 2022;132(4).
24. Hassan AO, Obeagu EI, Ajayi DT, Tolulope AA, Madekwe CC, Madekwe CC, Ikpenwa JN, Nakyeyune S. COVID 19 Omicron: The Origin, Presentation, Diagnosis. Prevention and Control. Asian Journal of Research in Infectious Diseases. 2022;11(1):25-33.
25. Ifeanyi OE. Emerging clinical & medical challenges and appropriate solutions during COVID-19 pandemic times. Med Clin Rev. 2020;6(5):108. **DOI:** 10.36648/2471-

299X.6.5.108
links/6012db46299bf1b33e30a9ec/Emerging-Clinical-Medical-Challenges-and-Appropriate-Solutions-during-Covid-19-Pandemic-Times.pdf.
26. Sharma S, Tyagi T, Antoniak S. Platelet in thrombo-inflammation: Unraveling new therapeutic targets. Frontiers in immunology. 2022; 13:1039843.
27. Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, Stamatelopoulos K, Terpos E, Kotanidou A, Hagberg CA, Dimopoulos MA. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. Journal of Infection. 2021;83(1):1-6.

Access this Article in Online	
Quick Response Code	Website: www.ijcrims.com
	Subject: Medical Sciences

How to cite this article:
Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu and Matthew Chibunna Igwe. (2023). COVID-19 and Blood Coagulation: Implications for Hemostasis. Int. J. Curr. Res. Med. Sci. 9(11): 16-22.
DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.004